A prospective Canadian study suggests that moving beyond narrow, cancer-specific molecular panels toward broader genomic ...
In an interview with Targeted Oncology™, Marcus Neubauer, MD, of The US Oncology Network, discusses the signs of physician ...
FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate ...
Survey of 200+ oncology physicians reveals top burnout drivers—EMR burden, leadership gaps, poor work-life boundaries, and ...
Varsetatug masetecan is a first-in-class ADC that pairs a monoclonal antibody against EpCAM with a topoisomerase 1 inhibitor ...
During a live event, Casey L. O'Connell, MD, and participants considered how white blood cell count may factor into risk ...
Months ahead of the target action date, the FDA recently approved the pan-RAS inhibitor daraxonrasib (Rasonque) for patients ...
Zanidatamab plus tislelizumab and chemotherapy reduced mortality risk by 28% versus trastuzumab plus chemotherapy, delivering ...
The FDA has granted fast track designation (FTD) to ERAS-0015, an oral pan-RAS molecular glue, clearing an expedited ...
The assays are now approved to assess HER2 status in gastric, gastroesophageal junction, and esophageal adenocarcinoma.
The recent FDA approval of iberdomide (Zenbexus) represents more than the approval of a single new drug for ...
Mehta, MD, discuss the changing treatment landscape and patients goals when treating chronic immune thrombocytopenia. Immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results